-

Imperative Care Announces Appointment of Tyler Binney to Board of Directors

Binney brings significant commercial and operational leadership in the global medical technology sector

CAMPBELL, Calif.--(BUSINESS WIRE)--Imperative Care, Inc. today announced the appointment of Tyler Binney to the company’s Board of Directors, effective immediately.

“At Imperative Care, we are intentional about building a seasoned leadership team that reflects a rich blend of strategic insight, diverse perspectives, and a shared commitment to elevate patient outcomes and expand care,” said Fred Khosravi, CEO and Chairman of Imperative Care. “We’re delighted to welcome Tyler at this significant stage in the company’s growth, as we further expand our impact and advance life-saving innovations for patients afflicted by runaway clot.”

Mr. Binney brings a proven track record of driving growth through strategic leadership and operational expertise. From April 2021 to November 2023, Mr. Binney served as President and Chief Executive Officer and as a member of the Board of Directors at Relievant Medsystems. During his tenure, he scaled the company’s commercial operations and successfully led its acquisition by Boston Scientific for more than $850 million. Prior to Relievant, Mr. Binney was the President and General Manager of Teleflex’s Interventional Urology Business Unit. He also served as Vice President of Sales at NeoTract, where he played a key role in the company’s $1.1 billion acquisition by Teleflex.

Mr. Binney currently serves as Chairman of the Board of iO Urology and a member of the Board of Directors of Intrinsic Therapeutics and ProVerum Medical.

“Imperative Care has taken an expansive patient-centered approach to addressing the scourge of stroke and other devastating vascular diseases,” said Mr. Binney. “I am honored to join the company’s Board of Directors as it focuses on applying operational discipline to expand its commercial presence and bring life-saving technologies to as many patients as possible.”

About Imperative Care, Inc.

Imperative Care is a commercial-stage medical technology company researching, developing and manufacturing connected innovations to elevate care for people affected by devastating vascular diseases such as stroke and pulmonary embolism. The company is addressing specific gaps in treatment and care to make an impact across the entire patient journey. Imperative Care is based in Campbell, Calif. https://imperativecare.com.

Contacts

Investor Contact:
Phil Nalbone
Vice President of Corporate Development and Investor Relations
Imperative Care, Inc.
Pnalbone@imperativecare.com

Media Contact:
Jana Chow
Imperative Care, Inc.
925-324-9846
jchow@imperativecare.com

Imperative Care, Inc.


Release Summary
Imperative Care, Inc. today announced the appointment of Tyler Binney to the company’s Board of Directors, effective immediately.
Release Versions

Contacts

Investor Contact:
Phil Nalbone
Vice President of Corporate Development and Investor Relations
Imperative Care, Inc.
Pnalbone@imperativecare.com

Media Contact:
Jana Chow
Imperative Care, Inc.
925-324-9846
jchow@imperativecare.com

More News From Imperative Care, Inc.

Imperative Care Secures FDA Clearance and Initial Cases of the Zoom 7X Catheter, the Newest Innovation in Ischemic Stroke Treatment

CAMPBELL, Calif.--(BUSINESS WIRE)--Imperative Care announces FDA 510(k) clearance and first patient cases with the novel Zoom 7X Catheter for aspiration thrombectomy procedures....

Imperative Care Presents Positive Imperative Trial Data from Patients Treated with Aspiration Thrombectomy for M2 Occlusions Using the Zoom System

CAMPBELL, Calif.--(BUSINESS WIRE)--Imperative Care, Inc. announces a late-breaking abstract with data evaluating aspiration with the Zoom System in stroke patients with M2 occlusions....

Imperative Care Announces Completion of Enrollment in the SYMPHONY-PE IDE Study for Treatment of Pulmonary Embolism

CAMPBELL, Calif.--(BUSINESS WIRE)--Imperative Care, Inc. announces enrollment completion in its SYMPHONY-PE Study, a pivotal IDE trial evaluating the Symphony Thrombectomy System....
Back to Newsroom